ZHOU De, ZHU Hong-hu, CHEN Xiao-mei. Venetoclax Plus Low-Dose Cytarabine for Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 91-94. DOI: 10.12019/j.issn.1671-5144.2022.02.005
|
Citation:
|
ZHOU De, ZHU Hong-hu, CHEN Xiao-mei. Venetoclax Plus Low-Dose Cytarabine for Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 91-94. DOI: 10.12019/j.issn.1671-5144.2022.02.005
|
ZHOU De, ZHU Hong-hu, CHEN Xiao-mei. Venetoclax Plus Low-Dose Cytarabine for Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 91-94. DOI: 10.12019/j.issn.1671-5144.2022.02.005
|
Citation:
|
ZHOU De, ZHU Hong-hu, CHEN Xiao-mei. Venetoclax Plus Low-Dose Cytarabine for Newly Diagnosed Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 91-94. DOI: 10.12019/j.issn.1671-5144.2022.02.005
|
DownLoad: